Evotec AG has entered a three-year collaboration agreement with UCB to provide in vitro pharmacology services to support UCB’s drug discovery projects across multiple target classes, particularly in the CNS space. Key activities will include assay development, compound profiling and mechanistic studies, and will provide UCB with access to Evotec’s expertise in in vitro pharmacology and electrophysiology. Financial details were not disclosed. Dr. Mario Polywka, chief operating officer of...